Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2026)

Guided Therapeutics has reported Amortization of Deferred Charges for 8 years, with the latest figure at $172000.0 in Q4 2025.

• Quarterly Amortization of Deferred Charges rose 352.63% year-over-year to $172000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $244000.0 (up 121.82% YoY) and the FY2025 annual result came in at $244000.0, up 121.82% from the prior year.
• Amortization of Deferred Charges improved to $172000.0 in Q4 2025 per GTHP's latest filing, from -$63000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $172000.0 in Q2 2021 and troughed at -$168000.0 in Q4 2021.
• A 5-year average of $32750.0 and a median of $32000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• The widest YoY moves for Amortization of Deferred Charges: up 352.63% in 2025, down 386.36% in 2025.
• Over 5 years, Amortization of Deferred Charges stood at -$168000.0 in 2021, then jumped by 119.05% to $32000.0 in 2022, then plunged by 37.5% to $20000.0 in 2023, then jumped by 90.0% to $38000.0 in 2024, then soared by 352.63% to $172000.0 in 2025.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $172000.0, -$63000.0, and $68000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.